pharmaphorum
DECEMBER 28, 2022
In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. Conducting internal pre-sale checks and looking at your level of compliance and licenses is a vital exercise. It is also an ideal opportunity to simplify as well as harmonise.
pharmaphorum
AUGUST 4, 2022
In particular, for the pharmaceutical industry, these talent shortages bring about a host of difficult challenges. This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Training and development.
pharmaphorum
JANUARY 24, 2023
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. ” Image from the Association of the British Pharmaceutical Industry (ABPI).
Expert insights. Personalized for you.
97 
Let's personalize your content